The earnings call reflects a positive overall sentiment, with strong revenue growth, successful international expansion, and significant pipeline progress. While there are challenges such as high operating expenses and variability in international sales, the highlights significantly outweigh the lowlights.

Company Guidance -

Q3 2025

During the call, Mirum Pharmaceuticals provided updated guidance for 2025, projecting full-year revenue to be between $490 million and $510 million, reflecting a near 50% year-over-year growth. This increase in guidance is driven by a strong second quarter performance, where total revenues reached $128 million, marking a 64% growth compared to the previous year. The growth is attributed primarily to the success of Livmarli, which generated approximately $57 million in net product sales in the U.S. and $31 million internationally. Additionally, the company saw robust performance from its bile acid portfolio, contributing approximately $40 million in revenue. Mirum is optimistic about its pipeline, with pivotal studies anticipated to yield results in the next 24 months, and is advancing its Phase II study for MRM-3379 in Fragile X syndrome. The company remains cash flow positive, with $322 million in cash, cash equivalents, and investments by the end of June 2025.

Strong Revenue Growth

Mirum Pharmaceuticals reported total revenues of $128 million for the second quarter of 2025, representing a 64% growth over the same quarter last year.

Increased Full-Year Revenue Guidance

Given the growth observed, Mirum raised its full-year revenue guidance for 2025 to be between $490 million and $510 million, indicating close to 50% top line growth.

International Expansion Success

Livmarli saw durable growth internationally with $31 million in net product sales, driven by expanding reimbursement and strong performance in partner markets, including a successful launch in Japan by partner Takeda.

Pipeline Progress

Significant advancements in the pipeline, including the VISTAS Phase IIb study in primary sclerosing cholangitis (PSC) on track for completion, and the initiation of a Phase II study for MRM-3379 in Fragile X syndrome by the end of the year.

Positive Financial Performance

Mirum was cash flow positive for the quarter with cash, cash equivalents, and investments totaling $322 million, a $29 million increase from the end of last year.

Mirum Pharmaceuticals (MIRM) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

MIRM Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 12, 2025	2025 (Q3)	-0.18 / -	-0.3	―	―	―
Aug 06, 2025	2025 (Q2)	-0.33 / -0.12	-0.52	76.92% (+0.40)	―
May 07, 2025	2025 (Q1)	-0.33 / -0.30	-0.54	44.44% (+0.24)	―
Feb 26, 2025	2024 (Q4)	-0.26 / -0.49	-0.63	22.22% (+0.14)
Nov 12, 2024	2024 (Q3)	-0.45 / -0.30	-0.57	47.37% (+0.27)
Aug 07, 2024	2024 (Q2)	-0.47 / -0.52	-1.94	73.20% (+1.42)	―
May 08, 2024	2024 (Q1)	-0.42 / -0.54	-0.8	32.50% (+0.26)	―
Feb 28, 2024	2023 (Q4)	-0.24 / -0.63	-0.99	36.36% (+0.36)
Nov 02, 2023	2023 (Q3)	-0.63 / -0.57	-1.02	44.12% (+0.45)
Aug 03, 2023	2023 (Q2)	-0.80 / -1.94	-0.84	-130.95% (-1.10)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

MIRM Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 06, 2025	$53.39	$59.82	+12.04%
May 07, 2025	$41.22	$45.24	+9.75%
Feb 26, 2025	$50.52	$46.98	-7.01%
Nov 12, 2024	$41.61	$42.28	+1.61%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Mirum Pharmaceuticals Inc (MIRM) report earnings?

Mirum Pharmaceuticals Inc (MIRM) is schdueled to report earning on Nov 12, 2025, After Close (Confirmed).

What is Mirum Pharmaceuticals Inc (MIRM) earnings time?

Mirum Pharmaceuticals Inc (MIRM) earnings time is at Nov 12, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is MIRM EPS forecast?

MIRM EPS forecast for the fiscal quarter 2025 (Q3) is -0.18.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing